These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 15023866)

  • 21. Modulation of peristalsis by NK3 receptor antagonism in guinea-pig isolated ileum is revealed as intraluminal pressure is raised.
    Sanger GJ; Tuladhar BR; Brown J; Aziz E; Sivakumar D; Furness JB
    Auton Autacoid Pharmacol; 2007 Apr; 27(2):105-11. PubMed ID: 17391280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurokinin-1 receptor antagonists inhibit the recruitment of opioid-containing leukocytes and impair peripheral antinociception.
    Rittner HL; Lux C; Labuz D; Mousa SA; Schäfer M; Stein C; Brack A
    Anesthesiology; 2007 Dec; 107(6):1009-17. PubMed ID: 18043070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
    Rumsey WL; Aharony D; Bialecki RA; Abbott BM; Barthlow HG; Caccese R; Ghanekar S; Lengel D; McCarthy M; Wenrich B; Undem B; Ohnmacht C; Shenvi A; Albert JS; Brown F; Bernstein PR; Russell K
    J Pharmacol Exp Ther; 2001 Jul; 298(1):307-15. PubMed ID: 11408556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Developmental expression of neurokinin-1 and neurokinin-3 receptors in the rat retina.
    Casini G; Brecha NC; Bosco L; Rickman DW
    J Comp Neurol; 2000 May; 421(2):275-87. PubMed ID: 10813787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tachykinin receptors in the gut: physiological and pathological implications.
    Holzer P; Holzer-Petsche U
    Curr Opin Pharmacol; 2001 Dec; 1(6):583-90. PubMed ID: 11757813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential therapeutic targets for neurokinin-1 receptor antagonists.
    Duffy RA
    Expert Opin Emerg Drugs; 2004 May; 9(1):9-21. PubMed ID: 15155133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tachykinin receptors and gastrointestinal motility: focus on humans.
    Lecci A; Altamura M; Capriati A; Maggi CA
    Eur Rev Med Pharmacol Sci; 2008 Aug; 12 Suppl 1():69-80. PubMed ID: 18924446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative, general pharmacology of SDZ NKT 343, a novel, selective NK1 receptor antagonist.
    Walpole CS; Brown MC; James IF; Campbell EA; McIntyre P; Docherty R; Ko S; Hedley L; Ewan S; Buchheit KH; Urban LA
    Br J Pharmacol; 1998 May; 124(1):83-92. PubMed ID: 9630347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tachykinin receptors and intestinal motility.
    Maggi CA; Catalioto RM; Criscuoli M; Cucchi P; Giuliani S; Lecci A; Lippi A; Meini S; Patacchini R; Renzetti AR; Santicioli P; Tramontana M; Zagorodnyuk V; Giachetti A
    Can J Physiol Pharmacol; 1997 Jun; 75(6):696-703. PubMed ID: 9276151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Localization of NK1 and NK3 receptors in guinea-pig brain.
    Yip J; Chahl LA
    Regul Pept; 2001 Apr; 98(1-2):55-62. PubMed ID: 11179779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.
    te Beek ET; Hay JL; Bullman JN; Burgess C; Nahon KJ; Klaassen ES; Gray FA; van Gerven JM
    Br J Clin Pharmacol; 2013 May; 75(5):1328-39. PubMed ID: 23067311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An Endogenous Tachykinergic NK2/NK3 Receptor Cascade System Controlling the Release of Serotonin from Colonic Mucosa.
    Kojima S; Tohei A; Ikeda M; Anzai N
    Curr Neuropharmacol; 2015; 13(6):830-5. PubMed ID: 26630961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances in neurokinin receptor antagonists.
    Gao Z; Peet NP
    Curr Med Chem; 1999 May; 6(5):375-88. PubMed ID: 10101218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intestinal anti-nociceptive behaviour of NK3 receptor antagonism in conscious rats: evidence to support a peripheral mechanism of action.
    Fioramonti J; Gaultier E; Toulouse M; Sanger GJ; Bueno L
    Neurogastroenterol Motil; 2003 Aug; 15(4):363-9. PubMed ID: 12846724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implications of tachykinins and calcitonin gene-related peptide in inflammatory bowel disease.
    Holzer P
    Digestion; 1998; 59(4):269-83. PubMed ID: 9693197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tachykinins and neuropsychiatric disorders.
    Chahl LA
    Curr Drug Targets; 2006 Aug; 7(8):993-1003. PubMed ID: 16918327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progress in the development of neurokinin 3 modulators for the treatment of schizophrenia: molecule development and clinical progress.
    Dawson LA; Porter RA
    Future Med Chem; 2013 Sep; 5(13):1525-46. PubMed ID: 24024945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolving concepts in functional gastrointestinal disorders: promising directions for novel pharmaceutical treatments.
    Hunt RH; Tougas G
    Best Pract Res Clin Gastroenterol; 2002 Dec; 16(6):869-83. PubMed ID: 12473296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Variation in mRNA expression of alpha-adrenergic, neurokinin and muscarinic receptors amongst four arteries of the rat.
    Phillips JK; Vidovic M; Hill CE
    J Auton Nerv Syst; 1997 Jan; 62(1-2):85-93. PubMed ID: 9021654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of novel NK3 receptor antagonists with reduced environmental impact.
    Yamamoto K; Okazaki S; Ohno H; Matsuda F; Ohkura S; Maeda K; Fujii N; Oishi S
    Bioorg Med Chem; 2016 Aug; 24(16):3494-500. PubMed ID: 27298001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.